Previous Article | Next Article 
Journal of Virology, May 2000, p. 4284-4290, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Apoptosis in Coxsackievirus B3-Caused Diseases: Interaction
between the Capsid Protein VP2 and the Proapoptotic Protein
Siva
Andreas
Henke,1,*
Heike
Launhardt,2
Katrin
Klement,1
Axel
Stelzner,1
Roland
Zell,1 and
Thomas
Munder2
Institute of Virology, Medical Center,
Friedrich Schiller University Jena,1 and
Department of Cell and Molecular Biology,
Hans-Knöll-Institut für Naturstoff-Forschung e.V., D-07745
Jena,2 Germany
Received 8 November 1999/Accepted 28 January 2000
 |
ABSTRACT |
Coxsackievirus B3 (CVB3) is a common factor in human myocarditis.
Apoptotic events are present in CVB3-induced disease, but it is
unclear how CVB3 is involved in apoptosis and which viral proteins may
induce the apoptotic pathway. In this report we demonstrate that the
human and murine proapoptotic protein Siva specifically interact
with the CVB3 capsid protein VP2. Furthermore, the transcription of
Siva is strongly induced in tissue of CVB3-infected mice and is present
in the same area which is positively stained for apoptosis, CD27, and
CD70. It has been proposed that Siva is involved in the
CD27/CD70-transduced apoptosis. Therefore, we suggest a molecular mechanism through which apoptotic events contributes to CVB3-caused pathogenesis.
 |
INTRODUCTION |
Coxsackievirus B3, a member of the
picornavirus family, is an important human pathogen. Most CVB3-caused
disease are mild, but some acute infections are severe and lethal.
Clinically, coxsackievirus infections are known to be associated with
different forms of subacute, acute, and chronic myocarditis (45,
50). CVB3 may cause cardiac arrhythmias and acute heart failure;
chronic forms of this disease may supervene, leading to dilated
cardiomyopathy, requiring heart transplantation, or to death. The
pathogenesis of coxsackievirus infection has been studied extensively
in different murine models, demonstrating that the outcome of the
disease is determined by complex interactions among several variables,
such as virus genotype (11, 25), mouse strains used
(11, 24), and the sex (23, 24, 26), age
(32), and immune status (18, 27, 37, 49) of the
host. In addition, the molecular biology of CVB3 is well documented,
especially in view of the availability of sequence data (9, 34,
35, 39, 46) and infectious cDNA molecules (30, 35) as
well as the characterization of the genome organization (36)
and RNA structures (52). Despite the accumulation of
molecular data, so far there are no virus-specific preventive or
therapeutic procedures available to protect humans against
coxsackievirus-induced heart diseases. In addition, the mechanisms how
CVB3 causes acute or chronic myocarditis are not well characterized
(6).
One detail of CVB3-induced pathogenesis is apoptosis. For example,
apoptotic processes are present in myocardial tissue of patients with dilated cardiomyopathy (42), and depending on the mouse strain and the virus variant used, apoptotic cells
are detectable in inflammatory lesions as well as myocardial tissue outside inflamed areas (12, 16, 18, 22, 25). However, it is
not established which cell type undergoes apoptosis. Furthermore, CVB3
infection of HeLa cells induces caspase-3 activation, but this may not
be responsible for the characteristic cytopathic effect produced by
coxsackieviruses (8). It is not clear how CVB3 is involved
in apoptotic processes and which viral proteins may interact
with host cell proteins. To study these possible protein-protein
interactions in more detail, we used the yeast two-hybrid system. A
HeLa cDNA expression library was screened for proteins that interact
with structural and functional proteins of CVB3. We identified the
interaction between the CVB3 capsid protein VP2 and the
proapoptotic protein Siva, which is involved in the
CD27/CD70-transduced apoptotic pathway (44). CD27, a member of the tumor necrosis factor receptor superfamily, is known to
be expressed in T and B cells. Two basic functions of CD27 signaling
are known so far. First, the binding of CD27 to CD70, a protein which
is also expressed in T and B cells, can provide costimulatory signals
in lymphocyte proliferation and immunoglobulin production (19,
44). For example, it was demonstrated that the cytoplasmic tail
of CD27 directly associates with Traf-2 and signals to the Jun
N-terminal kinase activation in primary murine lymph node T cells
(17). On the other hand, CD27 was shown to be involved in
apoptotic processes (44). The cytoplasmic tail of
CD27 lacks the death domain, but Siva, which has a death domain-like region, can bind to this part of CD27 under in vitro conditions. Overexpression of Siva in different cell lines induces apoptosis in the
absence of CD70. Therefore, only the association of CD27 with the
intracellular Siva can result in the induction of apoptotic events. Furthermore, under in vivo conditions Siva was also found to be present in a number of nonlymphatic tissues (44).
Using a rat model of acute ischemic injury, it was demonstrated
(43) that the rat equivalent of Siva is produced within the
kidney cells after injury and could be the mediator of
apoptosis via an interaction of CD27 which is expressed in the
kidney as well.
Using the murine model of CVB3 infection, we demonstrate that this
virus infection induced the transcription of the murine equivalent of
Siva (muSiva) in pancreas and heart tissue. The interaction between VP2
and muSiva was confirmed using a yeast two-hybrid approach.
Interestingly, transcription of muSiva as well as CD27-, CD70-, active
caspase-3-, and TUNEL (terminal deoxynucleotidyltransferase [TdT]-mediated dUTP-biotin nick end labeling) assay-positive cells were present in the same area of tissue in CVB3-infected mice. These
findings indicate a newly discovered mechanism by which apoptosis may contribute to coxsackievirus-dependent pathogenesis.
 |
MATERIALS AND METHODS |
Mice.
Inbred BALB/c (H-2dd) mice were
obtained from the Friedrich Schiller University breeding colony. Adult
males 7 to 9 weeks of age were used in this study. Experimental groups
consisted of a minimum of four mice, and experiments were repeated at
least twice and usually three or four times.
Viruses and cell lines.
The CVB3 (Nancy) variant used is a
cDNA-generated virus obtained after transfection of HeLa cells with
plasmid pCVB3M2, originally obtained by R. Zell (38). The
virus was propagated in HeLa cells and then purified and quantified as
described previously (18).
Constructions of plasmids.
The baits for the two-hybrid
screening were constructed as follows. Sequences specific for the
capsid proteins VP1 (851 bp), VP2 (788 bp), and the protease 2A (440 bp) were amplified by PCR from the CVB3 cDNA (35). The
upstream primer contains an NdeI site. The downstream
primers contain a BamHI site 3' to the stop codon. VP1, VP2,
and 2A samples were amplified at 94°C (5 min) for 1 cycle followed by
30 cycles at 94°C (1 min), 58°C (1 min), and 72°C (2 min), and a
final cycle at 72°C for 5 min in a total volume of 100 µl. The PCR
products were digested with NdeI and BamHI, gel
purified, and inserted between the appropriate sites of pAS2-1
(Clontech Laboratories Inc., Palo Alto, Calif.) to produce pAS2-1/VP1,
pAS2-1/VP2, and pAS2-1/2A. In a similar way, the coding sequences of
PV1-VP2 and TMEV-VP2 were PCR amplified using the cDNA of the relevant
virus as a template and cloned into pAS2-1. The fusion of the entire
human Siva (huSiva) protein to the Gal4 DNA-binding and activation
domains (Gal4BD and Gal4AD) was achieved by PCR amplification of the
identified prey plasmid lacking the first seven residues of huSiva,
using an upstream extended primer containing the missing codons and a
cleavage site for EcoRI. In the downstream primer, the stop
codon of huSiva was followed by an XhoI site. Digested PCR
fragments were ligated to the EcoRI/XhoI sites of
pGADGH (Clontech) or to the EcoRI/SalI sites of
pAS2-1, yielding Gal4AD-huSiva and Gal4BD-huSiva, respectively. The
same primers were applied for the generation of a glutathione
S-transferase (GST)-huSiva fusion using the vector
pGEX-4T-1 (Pharmacia, Freiburg, Germany). The in-frame fusions of all
PCR-amplified fragments were confirmed by sequencing.
Yeast strains, transformation, and two-hybrid analyses.
The
Saccharomyces cerevisiae strain used for the two-hybrid
studies was Y190 (MATa ura3-52 his3-200 lys2-801
ade2-101 trp1-901 leu2-3,-112 gal4
gal80
cyhr2
LYS2::GAL1UAS-HIS3TATA-HIS3
URA3::GAL1UAS-GAL1TATA-lacZ;
Clontech). Transformation of yeast cells was carried out by the method
of Klebe et al. (33). Yeast transformants were selected and
cultivated on SD synthetic medium (2% glucose and 0.67% yeast
nitrogen base without amino acids) supplemented with the appropriate
nutrients. S. cerevisiae Y190 expressing each of the
analyzed viral baits fused to the Gal4BD was transformed with a
Gal4AD-tagged HeLa cell cDNA library (Clontech), and the
cotransformants were initially selected for growth on medium lacking
histidine. To enhance the stringency of a two-hybrid interaction, the
medium was particularly supplemented with 40 mM 3-amino-1,2,4-triazole.
Growing yeast colonies were subsequently analyzed for
-galactosidase
expression using a colony lift filter assay with X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) as a
substrate as specified by Breeden and Nasmyth (7). The library plasmids of yeast cells expressing both reporter genes were
rescued by transformation of total yeast DNA into Escherichia coli HB101. Transformants were selected on M9 minimal medium
lacking leucine. To ensure the identification of the correct cDNA
preys, isolated plasmids were retransformed into yeast strain Y190
containing the appropriate bait proteins, and the cotransformants were
again tested for
-galactosidase activity.
GST pull-down experiments.
GST-huSiva was maintained and
expressed in E. coli BL21 as instructed by the manufacturer
(Pharmacia). The fusion protein was purified from crude bacterial cell
extracts with glutathione-Sepharose. Proteins of noninfected and
CVB3-infected HeLa cells were isolated by detaching the cells with 10 mM EDTA. Cells were centrifuged at 250 × g,
resuspended in NTE buffer (10 mM Tris-HCl [pH 7.4], 100 mM NaCl,
0.5% NP-40), and immediately vortexed for 30 s. Cell debris were
removed by centrifugation at 12,000 × g at 4°C for 20 min. Protein concentration of the clear supernatant was determined by the Bradford protein assay (Bio-Rad Laboratories, Hercules, Calif.).
The GST-pull down assays were performed by the protocol of MacDonald et
al. (40), with slight modification. Briefly, 30 µg of the
HeLa cell crude extract was incubated with 2 µg of GST-huSiva or 2 µg of GST alone in a total volume of 200 µl of binding buffer (20 mM Tris-HCl [pH 7.6], 100 mM NaCl, 0.1% NP-40, 0.1 nM
phenylmethylsulfonylfluoride, 1 mM dithiothreitol, pepstatin [50
µg/ml], aprotinin [2 µg/ml], leupeptin [2 µg/ml]).
Subsequently, 50 µl of a 50% slurry of glutathione-Sepharose,
equilibrated with the binding buffer, was added. The mixture was
incubated for 1 h at 4°C under slight shaking. Associated
proteins were pelleted by centrifugation and washed five times in 10 volumes of binding buffer. Finally the pellet was resuspended in 10 µl of sodium dodecyl sulfate sample buffer and analyzed for VP2
content by Western blotting. For this, the samples were loaded on a 10 to 20% Tris-glycine gradient gel. After electrophoresis, proteins were
electroblotted on a nitrocellulose membrane. Detection of proteins was
performed with the ProtoBlot II AP system (Promega Corp., Madison,
Wis.). As a primary antibody, a polyclonal anti-CVB3/VP4-2 rabbit
antibody (dilution 1:500) was applied, and color reaction was obtained
by using the Promega ProtoBlot II AP detection system.
Preparation and staining of routine histology.
Aseptically
removed pancreas and heart tissue was fixed with for at least 24 h
with 4% formaline and mounted in paraffin, and 6-µm sections were
cut and stained with hematoxylin-eosin.
Reverse transcription-PCR (RT-PCR).
Total RNA was isolated
from pancreas and heart tissues of infected and noninfected BALB/c mice
according to the acid guanidinium thiocyanate phenol chloroform method
described in detail by Chomczynski and Sacchi (10).
Following ultraspeed homogenization, RNA was extracted using 4 M
guanidinium thiocyanate-25 mM sodium citrate-0.5% sarcosyl-100 mM
mercapthoethanol (pH 7.0). DNA and protein contaminations were removed
by phenol-chloroform treatment. After ethanol precipitation, RNA
pellets were dissolved in diethyl pyrocarbonate-treated water and
incubated with DNase I (Boehringer, Mannheim, Germany) for 15 min at
room temperature (RT) to digest remaining DNA. The DNase I was
inactivated by adding 10 mM EDTA and heating to 65°C for 10 min.
Reverse transcription was performed as follows, using 5 µg of total
RNA. Random hexamer primers were allowed to anneal for 10 min at
70°C. Samples were heated to 42°C for 50 min using 200 U of
Superscript II reverse transcriptase (Life Technologies Inc.,
Rockeville, Md.) in buffer containing 20 mM Tris-HCl (pH 8.4), 50 mM
KCl, 1 mM dithiothreitol, and 2.5 mM MgCl2. The reaction was terminated by heating to 90°C for 5 min. The remaining RNA was
digested with E. coli RNase H (Life Technologies). Primers were designed to correspond to the 5' and 3' ends of murine Siva, VP2,
and
-actin cDNA sequences.
Immunohistochemistry.
Immunohistochemical studies were
carried out with cryomicrotome sections. Aseptically removed pancreas
and heart tissue was quickly frozen in frozen specimen embedding medium
(Cryomatrix; Life Technologies). For lymphocyte characterization,
10-µm sections were obtained, air dried for 2 h, fixed for 3 min
with acetone at RT, washed with Hanks solution, and treated with 0.04%
H2O2 to block cellular peroxidase activity.
Thereafter, sections were incubated separately with an avidin solution
(30 min, RT), biotin solution (30 min, RT), and a 2% nonfat dry milk
solution (30 min, RT) to block nonspecific binding. Between each
procedure, sections were washed three times with Hanks solution (3 min,
RT). All incubation and washing procedures to detect active caspase-3
were performed in the presence of 0.05% saponin. Primary antibodies
were applied for 14 h at 4°C. These consisted of rabbit
anti-active caspase-3 antibodies (clone 67341A; PharMingen, San Diego,
Calif.), Armenian hamster anti-CD27 antibodies (clone LG.3A10;
PharMingen), and rat anti-CD70 antibodies (clone FR70; PharMingen).
After a 12-min wash with Hanks solution, secondary antibodies
(biotin-conjugated anti-rabbit [PharMingen]; biotin-conjugated mouse
anti-hamster [PharMingen]; biotin-conjugated goat anti-rat [Jackson
ImmunoResearch Laboratories, West Grove, Pa.]) were applied for 30 min
at RT. A color reaction was obtained after washing of the slides for 12 min (RT) and sequential treatment with streptavidin-horseradish peroxidase conjugate and ACE Red peroxidase substrate kit (Camon Labor-Service GmbH, Wiesbaden, Germany). The sections were
counterstained with Mayer's hemalaun solution.
In situ hybridization.
Digoxigenin-labeled DNA probes for in
situ detection of viral RNA and RNA of muSiva were synthesized from
plasmid pCMV/VP1 or pAS2-1/muSiva by PCR using digoxigenin-labeled
nucleotides. Formalin-fixed, paraffin-embedded sections (6 µm)
obtained from pancreas and heart tissue were rehydrated by sequential
incubation with xylene, 100, 95, 70, and 50% ethanol, and
phosphate-buffered saline (PBS) for 5 min each and treated with
protease VIII solution (50 µg/ml; Sigma Biosciences, St. Louis, Mo.)
for 1 h at 37°C. After dehydration by sequential incubation with
70, 95, and 100% ethanol, sections were air dried, denatured at 90°C
for 8 min, and hybridized at 37°C for 18 h. Thereafter, slides
were washed twice at 37°C for 10 min. Background binding was blocked
with blocking solution (Kreatech Inc., Amsterdam, The Netherlands), and
the sections were incubated with antidigoxigenin antibody solution
(Boehringer) for 1 h at RT. A color reaction was obtained after
washing of the slides three times with PBS at RT and treatment with
nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate solution
(Boehringer). The sections were counterstained with eosin or
hematoxylin solution.
Apoptosis assay.
Apoptotic cells in pancreas and heart
tissue of CVB3-infected mice were detected by using a TACS Blue Label
(TBL) in situ apoptosis detection kit (Genzyme Corp.,
Cambridge, Mass.) as described in the Genzyme manual. Briefly,
formalin-fixed paraffin sections (6 µm) were obtained from pancreas
and heart tissue and rehydrated by sequential incubation with xylene,
100, 95, and 70% ethanol, distilled H2O, and PBS for 5 min
each. After protease K digestion for 15 min at RT and quenching of
endogenous peroxidase using 2% H2O2 solution
for 5 min at RT, tissue sections were incubated with the enzyme TdT,
reaction buffer with Co2+ cations, and digoxigenin-labeled
nucleotides. As a negative control, the TdT enzyme was omitted from the
protocol. Single positive cells were detected after color reaction with
TBL-streptavidin-horseradish peroxidase detection solution. The slides
were counterstained with eosin.
 |
RESULTS |
Coxsackievirus protein VP2 interacts with the
proapoptotic protein huSiva.
To identify human
proteins that interact with CVB3 proteins, we used a yeast two-hybrid
system based on the yeast Gal4 transactivator (15). As viral
baits we selected the CVB3 proteins VP1, VP2, and protease 2A. The
full-length cDNAs of these proteins fused to the yeast Gal4BD were
applied to screen a Gal4AD-tagged HeLa cell cDNA library. Our initial
selection criteria for positive interactors were the expression of the
reporter genes HIS3 and lacZ. Out of
approximately 2.2 × 105 analyzed yeast
cotransformants, we identified two candidate clones expressing proteins
which may bind to VP2. No reporter-positive clones were detected using
the baits VP1 and 2A. The cotransformation of Gal4BD-2A-containing
plasmids with the Gal4AD library plasmids resulted in a low
transformation frequency. Additionally, the obtained transformants grew
very slowly on selective media, which may indicate a toxic effect of 2A
expression on yeast cells as described earlier for the 2A protease of
poliovirus type 1 (3).
One of the identified preys interacting with VP2 encoded huSiva.
Recently, it has been shown that huSiva is involved in mediating CD27/CD70-transduced apoptotic processes (44).
Nucleotide sequencing revealed that the encoded fusion protein of the
original two-hybrid clone lacked the first seven residues of huSiva. To
reduce the probability of a false positive interaction, which often
occurs in two-hybrid screens (4), the entire huSiva sequence
was fused to the Gal4AD and analyzed for interaction with Gal4BD-VP2.
Yeast cells containing both fusion proteins induced lacZ
gene expression similarly to cells expressing Gal4BD-VP2 together with
Gal4AD-amino-terminally truncated huSiva (Fig.
1A). The reporter gene was not activated in cells expressing Gal4BD-VP2 or Gal4AD-Siva alone. These data indicated that the first seven amino acids of huSiva were not required
for the interaction with VP2.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 1.
Yeast two-hybrid filter lift assay demonstrating the
interaction between VP2 of CVB3 and huSiva. Plasmids carrying
Gal4BD-VP2 and Gal4AD-huSiva or the Gal4BD and Gal4AD alone were
transformed into yeast reporter strain Y190. The resulting cells were
analyzed for -galactosidase activity (A). Only the interaction of
Gal4BD-VP2 and Gal4AD-huSiva reconstituted an active Gal4 transcription
factor, demonstrated by blue-stained yeast colonies detected after
2 h of incubation with X-Gal (lane 3). GST pull-down experiments
confirmed the VP2-huSiva interaction in vitro (B). Thirty-microgram of
crude extract proteins of CVB3-infected HeLa cells was incubated with 2 µg of GST (lane 3) or 2 µg of GST-huSiva (lane 4). Protein
complexes were precipitated with glutathione-Sepharose and analyzed for
VP2 content as described in Materials and Methods. Lane 2, 30 µg of
CVB3-infected HeLa cell crude extract proteins; lane 5, 30 µg of
noninfected HeLa cell crude extract proteins. A prestained protein
marker was used as a size standard (lane M).
|
|
The specificity of the two-hybrid interaction between CVB3 VP2 and
huSiva was demonstrated by analyzing the ability of huSiva
to bind to
VP2 of two other picornaviruses, such as poliovirus
type 1 and
Theiler's murine encephalomyelitis virus, which are
also involved in
apoptotic processes (
1,
29). None of these
Gal4BD-tagged VP2 proteins were able to activate reporter gene
expression in Gal4BD-huSiva-expressing yeast reporter strains,
indicating that they did not interact with huSiva (data not shown).
To
confirm the two-hybrid in vivo binding of VP2 to huSiva, we
performed
in vitro assays using GST-huSiva and whole cell lysates
of
CVB3-infected HeLa cells. After the components were mixed,
the
huSiva-specific protein complexes were precipitated with
glutathione-Sepharose
and analyzed for VP2 content by Western blotting
using VP2-specific
polyclonal antibodies. Figure
1B shows that
GST-huSiva efficiently
precipitated endogenous VP2 from the
CVB3-infected cell extracts.
These data not only verified the
VP2-huSiva interaction found
in the yeast two-hybrid system by an in
vitro interaction but
also showed that huSiva selectively bound to VP2
even in the high
background of other cellular and viral components,
which were
contained in the crude
extracts.
Induction of muSiva transcription in different tissue of
CVB3-infected mice.
Comparison of the 189-amino-acid sequence of
huSiva (44) with the 177-amino-acid sequence of muSiva
(described by K. V. Prasad et al. [GenBank accession no.
AF033115]) revealed an identity of 71% (Fig.
2A). The entire muSiva cDNA sequence was obtained by PCR from the cDNA of CVB3-infected pancreas tissue and
fused to the DNA sequence coding for the yeast Gal4AD. The cotransformants of yeast strain Y190 expressing Gal4BD-VP2 and Gal4AD-muSiva were analyzed for lacZ activity by a filter
lift assay. As shown in Fig. 2B, the blue color could be detected after 2 h of incubation with X-Gal, demonstrating that VP2 also binds to
the muSiva. To study the VP2-Siva interaction under in vivo conditions,
we used the mouse model of CVB3-induced disease. Because apoptotic events seem to be involved in CVB3-caused
myocarditis, the induction of muSiva mRNA was analyzed in pancreas as
well as heart tissue of CVB3-infected mice by RT-PCR 1 day and 7 days p.i., respectively. As demonstrated in Fig. 2C, CVB3 caused the induction of high levels of muSiva mRNA in different tissue of individual mice compared to noninfected mice. This indicates that the
CVB3-caused induction of muSiva expression might be involved in
apoptosis during coxsackievirus-depending pathogenesis. Upon intraperitoneal (i.p.) inoculation of 106 PFU, CVB3
replicated primarily in tissue of the exocrine pancreas. High levels of
viral progenies were detectable at the first day of viral replication
(Fig. 3B), causing massive tissue destruction 1 to 3 days
postinfection (p.i.) as demonstrated in Fig.
3A. Thereafter, only the tissue
of the endocrine pancreas (islets of Langerhans) was still present 5 to
7 days p.i. Via blood circulation CVB3 entered the heart tissue,
causing myocytolysis and infiltration of mononuclear cells into
the infected area (Fig. 3A).

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 2.
CVB3-caused induction of muSiva. Sequence comparison
between the human (first row) and the murine (second row)
proapoptotic protein Siva reveals a 71% identity (A). The
interaction between VP2 of CVB3 and muSiva was confirmed using the
yeast two-hybrid system (B), demonstrated by the blue-colored yeast
colonies coexpressing Gal4BD-VP2 and Gal4AD-muSiva (lane 1). Male
BALB/c mice were infected with CVB3 i.p. RNA was isolated from pancreas
and heart tissue 1 or 7 days p.i. Transcription of muSiva, CVB3-VP2,
and -actin in tissue of individual noninfected or CVB3-infected mice
was analyzed by RT-PCR, demonstrating the induction of high levels of
muSiva mRNA only in tissue of CVB3-infected mice (C).
|
|

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 3.
Coxsackievirus-induced pathology in pancreas and heart
tissue of BALB/c mice. BALB/c mice were infected with CVB3 i.p. (A)
Pancreas tissue and heart tissue was isolated from infected animals 1 day and 7 days p.i., respectively, and from noninfected animals. After
hematoxylin-eosin staining, virus-caused tissue damage in the pancreas
was obvious, demonstrated by massive destruction of the exocrine
pancreas up to 7 days p.i. (original magnification, ×500). Only the
islets of Langerhans remained unaffected (arrows). In the heart tissue,
CVB3 infection caused massive inflammation accompanied by infiltration
of mononuclear cells 7 days p.i. (original magnification, ×500). (B)
At the indicated time points, eight mice were sacrificed and virus
titers were measured by plaque formation assays. Average titers and
standard deviations are shown as log10 values of PFU/0.1 g
of tissue.
|
|
Presence of apoptotic, CD27-positive, and
CD70-positive cells in different tissues of CVB3-infected
mice.
During CVB3 infection many host cell functions are altered,
including the induction or suppression of several genes encoding the
information of structural and nonstructural cellular proteins (51). These experiments indicate that CVB3 infections are
dynamic molecular processes in which timely interactions between viral and host proteins determine the outcome for both the virus and the host
cells. To analyze whether the CVB3-caused induction of muSiva
transcription (Fig. 2B) and the presence of high amounts of infectious
virus particles (Fig. 3B) were accompanied by apoptosis, the
TUNEL assay and immunohistochemistry to detect active caspase-3 protein
were applied, using pancreas and heart tissue 1 and 7 days p.i. As
shown in Fig. 4C and D, TUNEL assay- and
active caspase-3-positive cells were easily detectable in pancreas and
heart tissue in which viral RNA (Fig. 4B) as well as muSiva RNA (Fig.
4A) were present. Furthermore, CVB3 infections activated also the
expression of CD27 and CD70 in cells which were localized in the
infected area (Fig. 4E and F), indicating that the CD27/CD70
apoptotic pathway seemed to be induced in CVB3-caused
pathogenesis. Tissue sections of noninfected animals were negative
relating to in situ hybridization of muSiva and CVB3 as well as TUNEL
assay and immunohistochemistry of active caspase-3, CD27, and CD70
(data not shown).

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 4.
Detection of muSiva, apoptotic cells, and CD27-
and CD70-positive cells in CVB3-infected tissue. BALB/c mice were
infected with CVB3 i.p. Pancreas tissue and heart tissue were isolated
at 1 day and 7 days after infection, respectively, and used to perform
in situ hybridization studies (A and B), TUNEL assays (C), and
immunohistochemistry stainings (D to F). In the area of CVB3-infected
tissue (B), transcriptional activity of muSiva (A, arrows) as well as
TUNEL assay (C)- and active caspase-3 (D)-positive cells were
detectable. CVB3-caused inflammation also induced the accumulation of
CD27- and CD70-positive cells in both tissue (E and F). Original
magnification, ×1575.
|
|
 |
DISCUSSION |
In this report, we demonstrate that the structural protein VP2 of
CVB3 interacts specifically with the proapoptotic protein Siva. This observation was obtained using the yeast two-hybrid system
which was successfully applied for the identification of other
virus-host cell protein interactions. For example, this technique was
used to demonstrate that the IE2 protein of cytomegalovirus interacts
with several different human ribonucleoproteins (48) and
that the core protein of hepatitis C virus is able to bind to the
intracellular domain of the lympho-toxin
receptor, influencing hepatitis C virus-caused pathology (20).
CVB3 infections are usually accompanied by dramatic changes
of the cellular metabolism and the release of newly synthesized virus
particles. For a better understanding of this disease, several mouse
model systems demonstrating the complexity of CVB3-caused pathogenesis
have been established. Upon CVB3 binding to the coxsackievirus and
adenovirus receptor, the viral RNA enters the cytoplasm (5). There it is translated into a single polyprotein which is
proteolytically processed by virus-specific proteases into structural
and nonstructural proteins. The virus-encoded RNA-dependent RNA
polymerase transcribes negative-strand RNA, which is the template for
multiple rounds of virus genome synthesis. During this viral
replication several host cellular processes are altered, inducing host
cellular protein synthesis shutoff; e.g., the virus-specific protease
2A cleaves the eucaryotic initiation factor 4 gamma-1 and -2, stimulating the translation of uncapped mRNA like the CVB3 genome
(14, 41). In addition, recently it has been shown that 2A of
CVB3 can also inactivate both the poly(A)-binding protein
(31) as well as the cytoskeletal protein dystrophin
(2). Furthermore, 2B of CVB3 can modify plasma membrane and
endo-plasmic reticulum permeability (13), thus inducing an
increased level of cytosolic-free calcium (28, 47). Using in
vitro conditions, CVB3 infection results in tyrosine phosphorylation of
two cellular proteins, increasing viral progeny production
(21). With the help of the differential mRNA display
technique, it was demonstrated that in heart tissue of
CVB3-infected mice several genes were up- as well as downregulated in
comparison to cells of noninfected animals. Among these genes, mRNA levels of the mouse Nip21 were decreased. The human equivalent of
Nip21, Nip2, may interacts with the Bcl-2 protein to promote cell
survival. Downregulation of Nip21 by CVB3 infection may therefore increase myocyte cell death (51).
In our murine model of CVB3 infection, we were able to demonstrate that
the transcription of muSiva was increased in pancreas and heart tissue
in the presence of infectious virus particles. A molecular model that
illustrates the role of Siva in CD27/CD70-caused apoptosis is
shown in Fig. 5A. With or without binding
of CD70 to CD27 on the surface of the cellular membrane, Siva interacts with the cytoplasmic tail of CD27, providing death domain-like structures. The further events of this apoptotic pathway are
unknown so far. Due to the fact that CD27 belongs to the tumor
necrosis factor receptor superfamily, it is quite possible
that a protein which is similar to FADD
a protein which is necessary
for the Fas/Fas ligand-caused apoptosis
binds to Siva and
induces the activation of a putative caspase. Therefore, this
activation might be responsible for the activation of effector caspases
(e.g., caspase-3) and finally for the induction of programmed cell
death. In CVB3-infected cells, the expression of Siva is induced (Fig. 5B) and both CD27- and CD70-positive cells are present in the same area
of the infected tissue. Siva binds to the cytoplasmatic tail of CD27;
thereafter, VP2 of CVB3 may take the role of a putative FADD-like
protein, inducing apoptosis by caspase activation as shown in
Fig. 4D by detecting the active form of caspase-3. One other
possibility is that the direct binding between Siva and VP2 in the
cytoplasm may attract caspases and activate the death pathway in the
absence of CD70 ligation and CD27 complex formation. In addition,
in yeast Siva forms homodimeric complexes (data not shown), but whether
this observation has a physiological function in
apoptotic pathways is not clear.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Model for the putative induction of apoptosis in
CD27/Siva-mediated pathways (A) and possible role of VP2 in
CD27/Siva-mediated apoptotic events after CVB3 infection (B).
|
|
Given that coxsackievirus infections can cause pancreatitis as
well as acute or dilated cardiomyopathy and apoptotic events are present in virus-infected tissue, our results indicate a molecular mechanism by which the regulation of cell death proteins may be an
important early event of CVB3 infection before and after inflammation.
 |
ACKNOWLEDGMENTS |
We thank H.-P. Saluz for helpful discussions during the
preparation of this article.
This work was partly supported by grant HE 2910/2-1 MU 1395/1-1 from
the Deutsche Forschungsgemeinschaft.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Virology, Medical Center, Friedrich Schiller University, Winzerlaer
Str. 10, D-07745 Jena, Germany. Phone: (49) 3641 657215. Fax: (49) 3641 657202. E-mail: i6hean{at}rz.uni-jena.de.
 |
REFERENCES |
| 1.
|
Agol, V. I.,
G. A. Belov,
K. Bienz,
D. Egger,
M. S. Kolesnikova,
N. T. Raikhlin,
L. I. Romanova,
E. A. Smirnova, and E. A. Tolskaya.
1998.
Two types of death of poliovirus-infected cells: caspase involvement in the apoptosis but not cytopathic effect.
Virology
252:343-353[CrossRef][Medline].
|
| 2.
|
Badorff, C.,
G. H. Lee,
B. J. Lamphear,
M. E. Martone,
K. P. Campbell,
R. E. Rhoads, and K. U. Knowlton.
1999.
Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.
Nat. Med.
5:320-326[CrossRef][Medline].
|
| 3.
|
Barco, A., and L. Carrasco.
1995.
Poliovirus 2Apro expression inhibits growth of yeast cells.
FEBS Lett.
371:4-8[CrossRef][Medline].
|
| 4.
|
Bartel, P.,
C. T. Chien,
R. Sternglanz, and S. Fields.
1993.
Elimination of false positives that arise in using the two-hybrid system.
BioTechniques
14:920-924[Medline].
|
| 5.
|
Bergelson, J. M.,
J. A. Cunningham,
G. Droguett,
E. A. Kurt-Jones,
A. Krithivas,
J. S. Hong,
M. S. Horwitz,
R. L. Crowell, and R. W. Finberg.
1997.
Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.
Science
275:1320-1323[Abstract/Free Full Text].
|
| 6.
|
Bowles, N. E., and J. A. Towbin.
1998.
Molecular aspects of myocarditis.
Curr. Opin. Cardiol.
13:179-184[Medline].
|
| 7.
|
Breeden, L., and K. Nasmyth.
1985.
Regulation of the yeast HO gene.
Cold Spring Harbor Symp. Quant. Biol.
50:643-650[Abstract/Free Full Text].
|
| 8.
|
Carthy, C. M.,
D. J. Granville,
K. A. Watson,
D. R. Anderson,
J. E. Wilson,
D. Yang,
D. W. Hunt, and B. M. McManus.
1998.
Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells.
J. Virol.
72:7669-7675[Abstract/Free Full Text].
|
| 9.
|
Chapman, N. M.,
Z. Tu,
S. Tracy, and C. J. Gauntt.
1994.
An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.
Arch. Virol.
135:115-130[CrossRef][Medline].
|
| 10.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 11.
|
Chow, L. H.,
K. W. Beisel, and B. M. McManus.
1992.
Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury.
Lab. Investig.
66:24-31[Medline].
|
| 12.
|
Colston, J. T.,
B. Chandrasekar, and G. L. Freeman.
1998.
Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis.
Cardiovasc. Res.
38:158-168[Abstract/Free Full Text].
|
| 13.
|
Doedens, J. R., and K. Kirkegaard.
1995.
Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A.
EMBO J.
14:894-907[Medline].
|
| 14.
|
Etchison, D.,
S. C. Milburn,
I. Edery,
N. Sonenberg, and J. W. Hershey.
1982.
Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex.
J. Biol. Chem.
257:14806-14810[Abstract/Free Full Text].
|
| 15.
|
Fields, S., and O. Song.
1989.
A novel genetic system to detect protein-protein interactions.
Nature
340:245-246[CrossRef][Medline].
|
| 16.
|
Gebhard, J. R.,
C. M. Perry,
S. Harkins,
T. Lane,
I. Mena,
V. C. Asensio,
I. L. Campbell, and J. L. Whitton.
1998.
Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.
Am. J. Pathol.
153:417-428[Abstract/Free Full Text].
|
| 17.
|
Gravestein, L. A.,
D. Amsen,
M. Boes,
C. R. Calvo,
A. M. Kruisbeek, and J. Borst.
1998.
The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2.
Eur. J. Immunol.
28:2208-2216[CrossRef][Medline].
|
| 18.
|
Henke, A.,
S. Huber,
A. Stelzner, and J. L. Whitton.
1995.
The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.
J. Virol.
69:6720-6728[Abstract].
|
| 19.
|
Hintzen, R. Q.,
S. M. Lens,
G. Koopman,
S. T. Pals,
H. Spits, and R. A. van Lier.
1994.
CD70 represents the human ligand for CD27.
Int. Immunol.
6:477-480[Abstract/Free Full Text].
|
| 20.
|
Hsieh, T. Y.,
M. Matsumoto,
H. C. Chou,
R. Schneider,
S. B. Hwang,
A. S. Lee, and M. M. Lai.
1998.
Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K.
J. Biol. Chem.
273:17651-17659[Abstract/Free Full Text].
|
| 21.
|
Huber, M.,
H. C. Selinka, and R. Kandolf.
1997.
Tyrosine phosphorylation events during coxsackievirus B3 replication.
J. Virol.
71:595-600[Abstract].
|
| 22.
|
Huber, S. A.
1997.
Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice.
Lab. Investig.
76:691-701[Medline].
|
| 23.
|
Huber, S. A.,
J. Kupperman, and M. K. Newell.
1999.
Hormonal regulation of CD4+ T-cell responses in coxsackievirus B3-induced myocarditis in mice.
J. Virol.
73:4689-95[Abstract/Free Full Text].
|
| 24.
|
Huber, S. A., and P. A. Lodge.
1984.
Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens.
Am. J. Pathol.
116:21-29[Abstract].
|
| 25.
|
Huber, S. A.,
A. Mortensen, and G. Moulton.
1996.
Modulation of cytokine expression by CD4+ T cells during coxsackievirus B3 infections of BALB/c mice initiated by cells expressing the  + T-cell receptor.
J. Virol.
70:3039-3044[Abstract].
|
| 26.
|
Huber, S. A., and B. Pfaeffle.
1994.
Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3.
J. Virol.
68:5126-5132[Abstract/Free Full Text].
|
| 27.
|
Huber, S. A.,
J. E. Stone,
D. H. Wagner, Jr.,
J. Kupperman,
L. Pfeiffer,
C. David,
R. L. O'Brien,
G. S. Davis, and M. K. Newell.
1999.
 + T cells regulate major histocompatibility complex class II(IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis.
J. Virol.
73:5630-5636[Abstract/Free Full Text].
|
| 28.
|
Irurzun, A.,
L. Perez, and L. Carrasco.
1993.
Enhancement of phospholipase activity during poliovirus infection.
J. Gen. Virol.
74:1063-1071[Abstract/Free Full Text].
|
| 29.
|
Jelachich, M. L., and H. L. Lipton.
1999.
Restricted Theiler's murine encephalomyelitis virus infection in murine macrophages induces apoptosis.
J. Gen. Virol.
80:1701-1705[Abstract].
|
| 30.
|
Kandolf, R., and P. H. Hofschneider.
1985.
Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells.
Proc. Natl. Acad. Sci. USA
82:4818-4822[Abstract/Free Full Text].
|
| 31.
|
Kerekatte, V.,
B. D. Keiper,
C. Badorff,
A. Cai,
K. U. Knowlton, and R. E. Rhoads.
1999.
Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff?
J. Virol.
73:709-717[Abstract/Free Full Text].
|
| 32.
|
Khatib, R.,
J. L. Chason,
B. K. Silberberg, and A. M. Lerner.
1980.
Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas.
J. Infect. Dis.
141:394-403[Medline].
|
| 33.
|
Klebe, R. J.,
J. V. Harriss,
Z. D. Sharp, and M. G. Douglas.
1983.
A general method for polyethylene-glycol-induced genetic transformation of bacteria and yeast.
Gene
25:333-341[CrossRef][Medline].
|
| 34.
|
Klump, W. M.,
I. Bergmann,
B. C. Muller,
D. Ameis, and R. Kandolf.
1990.
Complete nucleotide sequence of infectious coxsackievirus B3 cDNA: two initial 5' uridine residues are regained during plus-strand RNA synthesis.
J. Virol.
64:1573-83[Abstract/Free Full Text].
|
| 35.
|
Knowlton, K. U.,
E. S. Jeon,
N. Berkley,
R. Wessely, and S. Huber.
1996.
A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.
J. Virol.
70:7811-7818[Abstract].
|
| 36.
|
Kräusslich, H. G.,
M. J. Nicklin,
C. K. Lee, and E. Wimmer.
1988.
Polyprotein processing in picornavirus replication.
Biochemie
70:119-130[Medline].
|
| 37.
|
Leipner, C.,
M. Borchers,
I. Merkle, and A. Stelzner.
1999.
Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.
J. Hum. Virol.
2:102-114[Medline].
|
| 38.
|
Lindberg, A. M.,
R. L. Crowell,
R. Zell,
R. Kandolf, and U. Pettersson.
1992.
Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3.
Virus Res.
24:187-196[CrossRef][Medline].
|
| 39.
|
Lindberg, A. M.,
P. O. Stalhandske, and U. Pettersson.
1987.
Genome of coxsackievirus B3.
Virology
156:50-63[CrossRef][Medline].
|
| 40.
|
MacDonald, P. N.,
D. R. Sherman,
D. R. Dowd,
S. C. Jefcoat, Jr., and R. K. DeLisle.
1995.
The vitamin D receptor interacts with general transcription factor IIB.
J. Biol. Chem.
270:4748-4752[Abstract/Free Full Text].
|
| 41.
|
Ohlmann, T.,
M. Rau,
V. M. Pain, and S. J. Morley.
1996.
The C-terminal domain of eucaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E.
EMBO J.
15:1371-1382[Medline].
|
| 42.
|
Olivetti, G.,
R. Abbi,
F. Quaini,
J. Kajstura,
W. Cheng,
J. A. Nitahara,
E. Quaini,
C. Di Loreto,
C. A. Beltrami,
S. Krajewski,
J. C. Reed, and P. Anversa.
1997.
Apoptosis in the failing human heart.
N. Engl. J. Med.
336:1131-1141[Abstract/Free Full Text].
|
| 43.
|
Padanilam, B. J.,
A. J. Lewington, and M. R. Hammerman.
1998.
Expression of CD27 and ischemia/reperfusion-induced expression of its ligand Siva in rat kidneys.
Kidney Int.
54:1967-1975[CrossRef][Medline].
|
| 44.
|
Prasad, K. V.,
Z. Ao,
Y. Yoon,
M. X. Wu,
M. Rizk,
S. Jacquot, and S. F. Schlossman.
1997.
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.
Proc. Natl. Acad. Sci. USA
94:6346-6351[Abstract/Free Full Text].
|
| 45.
|
Reyes, M. P., and A. M. Lerner.
1985.
Coxsackievirus myocarditis with special reference to acute and chronic effects.
Prog. Cardiovasc. Dis.
27:373-394[CrossRef][Medline].
|
| 46.
|
Tracy, S.,
N. M. Chapman, and Z. Tu.
1992.
Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice.
Arch. Virol.
122:399-409[CrossRef][Medline].
|
| 47.
|
van Kuppeveld, F. J.,
J. G. Hoenderop,
R. L. Smeets,
P. H. Willems,
H. B. Dijkman,
J. M. Galama, and W. J. Melchers.
1997.
Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release.
EMBO J.
16:3519-3532[CrossRef][Medline].
|
| 48.
|
Wang, Y. F.,
S. C. Chen,
F. Y. Wu, and C. W. Wu.
1997.
The interaction between human cytomegalovirus immediate-early gene 2 (IE2) protein and heterogeneous ribonucleoprotein A1.
Biochem. Biophys. Res. Commun.
232:590-594[CrossRef][Medline].
|
| 49.
|
Woodruff, J. F.
1970.
The influence of quantitated post-weaning undernutrition on coxsackievirus B3 infection of adult mice. II. Alteration of host defense mechanisms.
J. Infect. Dis.
121:164-181[Medline].
|
| 50.
|
Woodruff, J. F.
1980.
Viral myocarditis. A review.
Am. J. Pathol.
101:425-484[Medline].
|
| 51.
|
Yang, D.,
J. Yu,
Z. Luo,
C. M. Carthy,
J. E. Wilson,
Z. Liu, and B. M. McManus.
1999.
Viral myocarditis: identification of five differentially expressed genes in coxsackie-virus B3-infected mouse heart.
Circ. Res.
84:704-712[Abstract/Free Full Text].
|
| 52.
|
Zell, R., and A. Stelzner.
1997.
Application of genome sequence information to the classification of bovine enteroviruses: the importance of 5'- and 3'-nontranslated regions.
Virus Res.
51:213-229[CrossRef][Medline].
|
Journal of Virology, May 2000, p. 4284-4290, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lidsky, P. V., Romanova, L. I., Kolesnikova, M. S., Bardina, M. V., Khitrina, E. V., Hato, S. V., van Kuppeveld, F. J. M., Agol, V. I.
(2009). Interactions between Viral and Prokaryotic Pathogens in a Mixed Infection with Cardiovirus and Mycoplasma. J. Virol.
83: 9940-9951
[Abstract]
[Full Text]
-
Cottle, D. L., McGrath, M. J., Wilding, B. R., Cowling, B. S., Kane, J. M., D'Arcy, C. E., Holdsworth, M., Hatzinisiriou, I., Prescott, M., Brown, S., Mitchell, C. A.
(2009). SLIMMER (FHL1B/KyoT3) Interacts with the Proapoptotic Protein Siva-1 (CD27BP) and Delays Skeletal Myoblast Apoptosis. J. Biol. Chem.
284: 26964-26977
[Abstract]
[Full Text]
-
Chikhalya, A., Luu, D. D., Carrera, M., De La Cruz, A., Torres, M., Martinez, E. N., Chen, T., Stephens, K. D., Haas-Stapleton, E. J.
(2009). Pathogenesis of Autographa californica multiple nucleopolyhedrovirus in fifth-instar Anticarsia gemmatalis larvae. J. Gen. Virol.
90: 2023-2032
[Abstract]
[Full Text]
-
Resch, U., Schichl, Y. M., Winsauer, G., Gudi, R., Prasad, K., de Martin, R.
(2009). Siva1 is a XIAP-interacting protein that balances NF{kappa}B and JNK signalling to promote apoptosis. J. Cell Sci.
122: 2651-2661
[Abstract]
[Full Text]
-
Romanova, L. I., Lidsky, P. V., Kolesnikova, M. S., Fominykh, K. V., Gmyl, A. P., Sheval, E. V., Hato, S. V., van Kuppeveld, F. J. M., Agol, V. I.
(2009). Antiapoptotic Activity of the Cardiovirus Leader Protein, a Viral "Security" Protein. J. Virol.
83: 7273-7284
[Abstract]
[Full Text]
-
Fan, J., Son, K.-N., Arslan, S. Y., Liang, Z., Lipton, H. L.
(2009). Theiler's Murine Encephalomyelitis Virus Leader Protein Is the Only Nonstructural Protein Tested That Induces Apoptosis When Transfected into Mammalian Cells. J. Virol.
83: 6546-6553
[Abstract]
[Full Text]
-
Mihatsch, K., Nestler, M., Saluz, H.-P., Henke, A., Munder, T.
(2009). Proapoptotic protein Siva binds to the muscle protein telethonin in cardiomyocytes during coxsackieviral infection. Cardiovasc Res
81: 108-115
[Abstract]
[Full Text]
-
Rassmann, A., Henke, A., Zobawa, M., Carlsohn, M., Saluz, H.-P., Grabley, S., Lottspeich, F., Munder, T.
(2006). Proteome alterations in human host cells infected with coxsackievirus B3. J. Gen. Virol.
87: 2631-2638
[Abstract]
[Full Text]
-
Zhang, H. M., Yuan, J., Cheung, P., Chau, D., Wong, B. W., McManus, B. M., Yang, D.
(2005). Gamma Interferon-Inducible Protein 10 Induces HeLa Cell Apoptosis through a p53-Dependent Pathway Initiated by Suppression of Human Papillomavirus Type 18 E6 and E7 Expression. Mol. Cell. Biol.
25: 6247-6258
[Abstract]
[Full Text]
-
Chu, F., Barkinge, J., Hawkins, S., Gudi, R., Salgia, R., Kanteti, P. V.S.
(2005). Expression of Siva-1 Protein or Its Putative Amphipathic Helical Region Enhances Cisplatin-Induced Apoptosis in Breast Cancer Cells: Effect of Elevated Levels of BCL-2. Cancer Res.
65: 5301-5309
[Abstract]
[Full Text]
-
Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., Wessely, R.
(2005). Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice. Circulation
111: 1583-1592
[Abstract]
[Full Text]
-
Feuer, R., Pagarigan, R. R., Harkins, S., Liu, F., Hunziker, I. P., Whitton, J. L.
(2005). Coxsackievirus Targets Proliferating Neuronal Progenitor Cells in the Neonatal CNS. J. Neurosci.
25: 2434-2444
[Abstract]
[Full Text]
-
Kim, S.-M., Park, J.-H., Chung, S.-K., Kim, J.-Y., Hwang, H.-Y., Chung, K.-C., Jo, I., Park, S.-I., Nam, J.-H.
(2004). Coxsackievirus B3 Infection Induces cyr61 Activation via JNK To Mediate Cell Death. J. Virol.
78: 13479-13488
[Abstract]
[Full Text]
-
Py, B., Slomianny, C., Auberger, P., Petit, P. X., Benichou, S.
(2004). Siva-1 and an Alternative Splice Form Lacking the Death Domain, Siva-2, Similarly Induce Apoptosis in T Lymphocytes via a Caspase-Dependent Mitochondrial Pathway. J. Immunol.
172: 4008-4017
[Abstract]
[Full Text]
-
Del Rio, M., Imam, A., DeLeon, M., Gomez, G., Mishra, J., Ma, Q., Parikh, S., Devarajan, P.
(2004). The Death Domain of Kidney Ankyrin Interacts with Fas and Promotes Fas-Mediated Cell Death in Renal Epithelia. J. Am. Soc. Nephrol.
15: 41-51
[Abstract]
[Full Text]
-
Feuer, R., Mena, I., Pagarigan, R. R., Harkins, S., Hassett, D. E., Whitton, J. L.
(2003). Coxsackievirus B3 and the Neonatal CNS: The Roles of Stem Cells, Developing Neurons, and Apoptosis in Infection, Viral Dissemination, and Disease. Am. J. Pathol.
163: 1379-1393
[Abstract]
[Full Text]
-
Colon-Ramos, D. A., Irusta, P. M., Gan, E. C., Olson, M. R., Song, J., Morimoto, R. I., Elliott, R. M., Lombard, M., Hollingsworth, R., Hardwick, J. M., Smith, G. K., Kornbluth, S.
(2003). Inhibition of Translation and Induction of Apoptosis by Bunyaviral Nonstructural Proteins Bearing Sequence Similarity to Reaper. Mol. Biol. Cell
14: 4162-4172
[Abstract]
[Full Text]
-
Klingel, K., Schnorr, J.-J., Sauter, M., Szalay, G., Kandolf, R.
(2003). {beta}2-Microglobulin-Associated Regulation of Interferon-{gamma} and Virus-Specific Immunoglobulin G Confer Resistance Against the Development of Chronic Coxsackievirus Myocarditis. Am. J. Pathol.
162: 1709-1720
[Abstract]
[Full Text]
-
Zhang, H. M., Yanagawa, B., Cheung, P., Luo, H., Yuan, J., Chau, D., Wang, A., Bohunek, L., Wilson, J. E., McManus, B. M., Yang, D.
(2002). Nip21 Gene Expression Reduces Coxsackievirus B3 Replication by Promoting Apoptotic Cell Death via a Mitochondria-Dependent Pathway. Circ. Res.
90: 1251-1258
[Abstract]
[Full Text]
-
Kuo, R.-L., Kung, S.-H., Hsu, Y.-Y., Liu, W.-T.
(2002). Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J. Gen. Virol.
83: 1367-1376
[Abstract]
[Full Text]
-
Xue, L., Chu, F., Cheng, Y., Sun, X., Borthakur, A., Ramarao, M., Pandey, P., Wu, M., Schlossman, S. F., Prasad, K. V. S.
(2002). Siva-1 binds to and inhibits BCL-XL-mediated protection against UV radiation-induced apoptosis. Proc. Natl. Acad. Sci. USA
99: 6925-6930
[Abstract]
[Full Text]
-
Luo, H., Yanagawa, B., Zhang, J., Luo, Z., Zhang, M., Esfandiarei, M., Carthy, C., Wilson, J. E., Yang, D., McManus, B. M.
(2002). Coxsackievirus B3 Replication Is Reduced by Inhibition of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway. J. Virol.
76: 3365-3373
[Abstract]
[Full Text]
-
Henke, A., Zell, R., Ehrlich, G., Stelzner, A.
(2001). Expression of Immunoregulatory Cytokines by Recombinant Coxsackievirus B3 Variants Confers Protection against Virus-Caused Myocarditis. J. Virol.
75: 8187-8194
[Abstract]
[Full Text]
-
Jelachich, M. L., Lipton, H. L.
(2001). Theiler's Murine Encephalomyelitis Virus Induces Apoptosis in Gamma Interferon-Activated M1 Differentiated Myelomonocytic Cells through a Mechanism Involving Tumor Necrosis Factor Alpha (TNF-{alpha}) and TNF-{alpha}-Related Apoptosis-Inducing Ligand. J. Virol.
75: 5930-5938
[Abstract]
[Full Text]
-
Peng, T., Sadusky, T., Li, Y., Coulton, G. R., Zhang, H., Archard, L. C.
(2001). Altered expression of Bag-1 in Coxsackievirus B3 infected mouse heart. Cardiovasc Res
50: 46-55
[Abstract]
[Full Text]
-
Cao, C., Ren, X., Kharbanda, S., Koleske, A., Prasad, K. V. S., Kufe, D.
(2001). The ARG Tyrosine Kinase Interacts with Siva-1 in the Apoptotic Response to Oxidative Stress. J. Biol. Chem.
276: 11465-11468
[Abstract]
[Full Text]